EMERGE BIOSCIENCE PTE LTD: biosimilar supplement approved for YUSIMRY

EMERGE BIOSCIENCE PTE LTD: biosimilar supplement approved for YUSIMRY. Dated 40 days ago, it serves as a historical benchmark. Score 30/100. As of 2026-11-04, from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration).

Data as of · Compiled by Zalwin from openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)

Free preview: all 7 published fields of this record are shown below. Locked: 499 related FdaApprovalPulse records and the 4-column CSV export.

FieldValue
SponsorEMERGE BIOSCIENCE PTE LTD
ProductYUSIMRY
Generic / ingredientADALIMUMAB-AQVH
ApprovalOther drug supplement
ApplicationBLA761216 supplement 11
Decided2026-09-25
Panel / classINJECTABLE, INJECTION
Peer records CSV (500 records) 🔒 Click to unlock →
CRM-ready export with official source URLs 🔒 Click to unlock →

View the official record

Markdown version

Watch EMERGE BIOSCIENCE PTE LTD

Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.

Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.

Free first: a 10-record sample of records

See the real columns before you buy. One confirmation email, nothing else unless you opt in.

Unlock EMERGE BIOSCIENCE PTE + 500 peer records (CSV)

Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Product · Approval · Decided · official source URL

  • Source agency: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration)
  • Record date: 2026-09-25
  • Data refreshed: 2026-11-04
  • Refunds on request within 14 days

Search all records free →

Top FdaApprovalPulse records: Instylla, Inc. · Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Cerenovus, Inc. · Advanced Medical Solutions Limited · Lenstec, Inc. · Browse all by state and category →

LIVE PUBLIC DATA Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) · Last refreshed: Wed, 04 Nov 2026 06:06:18 GMT

Is this your business? Add a "Listed on Zalwin" badge to your site

Paste this snippet into your website. It links to this public record; nothing is tracked on your site.

Listed on Zalwin badge preview

Search, filter and export more FdaApprovalPulse records

Run instant live search with these filters Download free sample CSV

✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days

30 / 100 Score

    What is the FdaApprovalPulse record for EMERGE BIOSCIENCE PTE LTD?

    The FDA approved YUSIMRY (BLA761216 supplement 11) for EMERGE BIOSCIENCE PTE LTD on 2026-09-25: other drug supplement.

    How does EMERGE BIOSCIENCE PTE LTD compare to other FdaApprovalPulse records?

    It is 40 days old, still within a typical 45-day follow-up window. Its Score of 30/100 is modest; treat it as background rather than a priority.

    EMERGE BIOSCIENCE PTE LTD vs. top 3 peers

    OrganizationRecord date
    EMERGE BIOSCIENCE PTE LTD2026-09-25
    AMGEN INC2026-09-29
    TEVA PHARMACEUTICALS, INC.2026-09-29
    CELLTRION INC2026-09-29

    Related records

    FdaApprovalPulse: Other drug supplement

    How to monitor EMERGE BIOSCIENCE PTE LTD and peer other drug supplement records

    Get new FdaApprovalPulse records like EMERGE BIOSCIENCE PTE LTD by email (free, weekly)

    We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.

    Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.

    See this week's digest

    Get new approvals in your categories

    FdaApprovalPulse emails new device and drug approvals matching your approval types.

    See plans

    ✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days

    From openFDA (PMA and Drugs@FDA). openFDA can lag FDA decisions by days to weeks. Drug supplement types follow the FDA submission class (labeling and REMS, manufacturing/CMC, efficacy, other). Company and product level only. Verify on FDA databases before relying on an approval.

    Often used together